Delamanid

DB11637ApprovedInvestigationalSmall molecule

Delamanid is an antibiotic used to treat multidrug resistant tuberculosis. Delamanid is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall.

Chemical structure of Delamanid
Mechanism
Curator reviewed · 6 references
Primary indication
Indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.Curator reviewed · 1 structured indication
Formula / weight
C25H25F3N4O6 · 534.492 g/mol (avg)
First approval
European Union, 2016
Also known as
(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole
Code names
OPC-67683
Brand names
  • Deltyba

Resolves to

Clinical / RWD
Structure
InChIKeyXDAOLTSRNUSPPH-XMMPIXPASA-NSMILESC[C@]1(COC2=CC=C(C=C2)N2CCC(CC2)OC2=CC=C(OC(F)(F)F)C=C2)CN2C=C(N=C2O1)[N+]([O-])=O
Targets

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
464Drug interactionsStructured to mechanism, not free text
Sign in
41Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
13Marketed productsAcross 5 countries and 4 labellers
Sign in
1ATC codeIncluding every combination product, plus 10 drug categories
Sign in
20+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Delamanid, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account